Skin Toxicity Seen In Other DPP-4 Inhibitors Missing In Januvia NDA – FDA Review
FDA’s request for additional primate studies to assess potential skin toxicity stemmed from findings with other agents of the same class, agency review documents show.
FDA’s request for additional primate studies to assess potential skin toxicity stemmed from findings with other agents of the same class, agency review documents show.